Clinical trial · Interventional
Safety and Efficacy of Unrelated Cord Blood Transplantation for Adult Patients With Hematologic Malignancies
Phase 1/2 Study of Cord Blood Transplantation From Unrelated Donor for Adult Patients With Hematologic Malignancies Using Myeloablative Conditioning Regimen
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The primary purpose of this study is to evaluate the safety and efficacy of cord blood transplantation for adult patients with hematologic malignancies including refractory acute leukemia. The transplant procedure was determined in detail according to the previously published report showing a high survival, so that the investigators could expect a similar result.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Acute Lymphoblastic Leukemia | Acute Lymphoblastic Leukemia | ONTOLOGY_EXACT | 0.98 |
| Acute Myelogenous Leukemia | Acute Myeloid Leukemia | ALIAS | 0.90 |
| Chronic Myelogenous Leukemia | Myeloid Leukemia | CURATED_BROADER | 0.80 |
| Myelodysplastic Syndrome | Myelodysplastic Syndrome | CURATED_BROADER | 0.80 |
Interventions
Interventions (4)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Cord blood transplantation | Procedure | — | UNRESOLVED |
| cyclophosphamide | Drug | Cyclophosphamide | ALIAS |
| cytarabine | Drug | Cytarabine | ALIAS |
| TBI | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Non-relapse mortality at 1 year
- timeFrame
- 1 year
Secondary outcomes (7)
- measure
- Engraftment
- timeFrame
- day 56
- measure
- Disease free survival
- timeFrame
- 1 year
- measure
- Overall survival
- timeFrame
- 1 year
- measure
- Incidence of acute and chronic graft-versus-host disease
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 20 Years
- Maximum age
- 55 Years
Show eligibility criteria text
Inclusion Criteria: * Clinical diagnosis of acute leukemia, chronic myelogenous leukemia, and myelodysplastic syndrome * Lack of HLA-identical or 1 locus mismatched related donor * Age over 20, and under 55 * Performance status 0 or 1 * No moderate or sever organ dysfunction (liver, kidney, heart, lungs) * No anti-HLA antibody * Informed consent was obtained Exclusion Criteria: * Uncontrollable diabetes * Uncontrollable hypertension * Active infection * TPHA, HBs-Ag, HCV-Ab positive * HTLV-I, HIV positive
References
Publications (0)
Data not yet available